(Q36979320)

17 August 2017

1 reference

title

A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia (English)

1 reference

17 August 2017

1 reference

5

Joel W Hay

1 reference

17 August 2017

Kimbach T Carpiuc

1

1 reference

17 August 2017

Jennifer M Stephens

series ordinal

2

1 reference

17 August 2017

Marc F Botteman

series ordinal

3

1 reference

17 August 2017

Weiwei Feng

series ordinal

4

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

1 reference

17 August 2017

8

1 reference

17 August 2017

16

1 reference

17 August 2017

2775-2787

1 reference

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Recent approaches in acute lymphoblastic leukemia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

The epidemiology of disease expenses. The costs of caring for children with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2775

10.1517/14656566.8.16.2775

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference